SCHEMBL22601441

SCHEMBL22601441

CC(C)c1ncccc1-c1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
ATAD2 Q6PL18 1/20 0.39
PDE10A Q9Y233 1/20 0.38
KCNA5 P22460 1/20 0.38
KCNH2 Q12809 1/20 0.38
NOTUM Q6P988 1/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.38
PDK2 Q15119 1/20 0.38
MAPK10 P53779 3/20 0.37
MAPK14 Q16539 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15723950 0.86 PTGS1 (0.44) MAPTKCNA5KCNH2ALDH1A1TSHR
SCHEMBL15723877 0.82 COMT (0.46) MAPTALDH1A1SMN1; SMN2PDK2ADRA2A
SCHEMBL14555509 0.82 PTGS2 (0.45) MAPTLMNANOTUMALDH1A1SMN1; SMN2
SCHEMBL15723977 0.81 CYP2A6 (0.52) MAPTLMNAKCNA5ALDH1A1SMN1; SMN2
SCHEMBL9963326 0.81 GCGR (0.42) MAPK10MAPK14
SCHEMBL18853955 0.81 TDP1 (0.41) MAPTALDH1A1SMN1; SMN2TSHRNPC1
SCHEMBL26627849 0.81 USP7 (0.44) MAPTSMN1; SMN2PDK2ADRA2AADRA2B
SCHEMBL15723954 0.78 PTGS2 (0.41) MAPTKCNA5KCNH2ALDH1A1TSHR
SCHEMBL14555450 0.78 CYP2A6 (0.47) ADRA2AADRA2BADRA2CNPC1
SCHEMBL15723893 0.78 CLK4 (0.55) MAPTLMNAALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 HEPAGENE THERAPEUTICS, INC. (VG) 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 ATF1, ERN1, MAP3K1 MAPT 539/4885LMNA 3233/4885ATAD2 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.